Data completeness
2/8 — Basic
ISONIAZID by Eli Lilly and Company is clinical pharmacology within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Isoniazid is a small-molecule bactericidal agent that inhibits mycolic acid synthesis in the bacterial cell wall, rendering it effective against actively growing Mycobacterium tuberculosis. It is a foundational first-line antituberculous drug administered orally with rapid absorption and broad tissue penetration including the CNS. The drug is metabolized via acetylation with genetically determined pharmacokinetic variability affecting systemic exposure and toxicity risk.
Pre-Launch
Pre-launch NDA stage suggests early-stage commercialization planning with emerging team formation; career opportunity window for foundational commercial roles.
Mechanism of Action
CLINICAL PHARMACOLOGY Within 1 to 2 hours after oral administration, isoniazid produces peak blood levels which decline to 50 percent or less within 6 hours. It diffuses readily into all body fluids (cerebrospinal, pleural, and ascitic fluids), tissues, organs, and excreta (saliva, sputum, and…
Indications
Worked on ISONIAZID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.